Behavioral and neurochemical effects induced by subchronic 1-deprenyl administration

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 3, 1997, Pages 649-655

  Molinengo, Luigi ^a   Ghi, Piera ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Deprenyl; Memory retention; Neurochemical effects; Staricase maze

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; ALPHA ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; NORADRENALIN; SELEGILINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN CORTEX; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; DOSE RESPONSE; HIPPOCAMPUS; MALE; MEMORY CONSOLIDATION; NONHUMAN; OLFACTORY SYSTEM; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY;

ACETYLCHOLINE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DOPAMINE; KINETICS; MALE; MAZE LEARNING; MONOAMINE OXIDASE INHIBITORS; NOREPINEPHRINE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, MUSCARINIC; SELEGILINE; SEROTONIN;

EID: 0030855873     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00001-4     Document Type: Article

References (27)

1. Beani L., Bianchi C. The extraction of acetylcholine in small samples of cerebral tissue. J. Pharm. Pharmacol. 15:1963;281-282.
2. Berry M. D., Juorio A. V., Paterson I. A. The functional role of monoamineoxidases A and B in the mammalian central nervous system. Prog. Neurobiol. 42:1994;375-391.
3. Berry M. D., Juorio A. V., Paterson I. A. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog. Neurobiol. 44:1994;141-161.
4. Brandeis R., Sapir M., Kapon Y., Borelli G., Valsecchi B. Improvement of cognitive function by MAO-B inhibitor L-deprenyl in aged rats. Pharmacol. Biochem. Behav. 39:1991;297-304.
5. Ehrenstrom F., Johansson P. A method for very rapid determination of catechols using ion-pairing reverse phase electrochemical detection. Effects of L-DOPA treatment on cathecol content in various brain structures Life Sci. 36:1985;867-879.
6. Elsworth J. D., Sandler M., Lees A. J., Ward C., Stern G. M. The contribution of amphetamine metabolites of (-)deprenyl to its antiparkinsonian properties. J. Neural. Transm. 54:1982;105-110.
7. Garrick N., Murphy D. L. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology. 72:1980;27-33.
8. Gelowitz D. L., Richardson J. S., Widhart T. B., Yu P. H., Lai C. T. Chronic L-deprenyl or L-amphetamine. Equal cognitive enhancement unequal MAO inhibition Pharmacol. Biochem. Behav. 44:1994;41-45.
9. Glossman H., Hornung R. Alpha-adrenoceptors in rat brain. Sodium changes the affinity of agonists for prazosin sites Eur. J. Pharmacol. 61:1980;407-408.
10. Forloni G. L., Bidzinski A., Fusi R., Ladinsky H., Consolo S. Striatal cholinergic function reflects differences in D-2 dopaminergic receptor activation. Life Sci. 41:1987;1717-1723.
11. Heinonen E. H., Myllyla V., Sotaniemi K., Lamintausta R., Salonen J. S., Anttila M., Savijarvi M., Katila M., Rinne U. K. Pharmacokinetics and metabolism of seligiline. Acta Neurol. Scand. 80:1989;83-91.
12. Keller O., Oke A., Mefford I., Adams R. N. Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping. Life Sci. 19:1976;995-1004.
13. Knoll J. -)Deprenyl (seligiline, Movergan) facilitates the nigrostriatal neuron. J. Neural. Transm. 25(suppl.):1987;45-46.
14. Knoll J. The pharmacology of seligiline (-)deprenyl. New aspects. Acta Neurol. Scand. 80(suppl.):1989;83-91.
15. Knoll J., Miklya I. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity. Rationale for prophylactic (-)deprenyl (seligiline) medication Life Sci. 56:1995;611-620.
16. Lowry O. H., Resenbrough N. J., Farr A. L., Randall R. J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
17. Mangoni A., Grassi M. P., Frattola L., Piolti R., Bassi S., Motta A., Marcone A., Smirne S. Effects of a MAO-B inhibitor in the treatment of Alzheimer disease. Eur. Neurol. 31:1991;100-107.
18. Marsden C. D. Parkinson's disease. Lancet. 335:1990;948-952.
19. Molinengo L., Ghi P., Oggero L., Orsetti M. Behavioral and neurochemical modifications caused by a chronic alpha-methyl-paratyrosine administration. Pharmacol. Biochem. Behav. 39:1991;437-442.
20. Molinengo L., Scordo I., Pastorello B. Action of caffeine, L-PIA and their combination on memory retention in the rat. Life Sci. 54:1994;1247-1250.
21. Molinengo L., Orsetti M., Pastorello B., Scordo I., Ghi P. The action of arecoline on retrieval and memory storage evaluated in the staircase maze. Neurobiol. Learn. Mem. 63:1995;167-173.
22. Paterson A. V., Juorio M., Berry M. D., Zhu M. Y. Inhibition of monoamino oxidase-B by (-)deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J. Pharm. Exp. Ther. 258:1991;1019-1026.
23. Paterson I. A., Juorio A. V., Boulton A. A. 2-Phenylethylamine. A modulator of catecholamine transmission in the mammalian central nervous system? J. Neurochem. 55:1990;1827-1837.
24. Piccinin G. L., Finali G., Piccirilli M. Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. Clin. Neuropharmacol. 13:1990;147-163.
25. Stadler H., Lloyd K. G., Gadea-Ciria M., Bartholini G. Enhanced striatal acetylcholine release by chlorpromazine and its reversal by apomorphine. Brain Res. 55:1973;476-480.
26. Tariot P. N., Cohen R. M., Sunderland T., Newhouse P. A., Yount D., Mellow A. M., Weingartner H., Mueller A., Murphy D. L. L-deprenyl in Alzheimer's disease. Arch. Gen. Psychiatr. 44:1987;427-433.
27. Yamamura H. L., Snyder S. H. Muscarinic cholinergic binding in rat brain. Proc. Natl. Acad. Sci. USA. 71:1974;1725-1729.